Please assess the completion status of the following clinical trial:

Trial Title: Sofosbuvir and Daclatasvir for Treating Hepatitis C in 200 Patients Co-infected With Human Immunodeficiency Virus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Positive qualitative hepatitis C virus RNA test on two occasions at least 6 months apart~* Positive human immunodeficiency virus test~Exclusion Criteria:~* Heart rate \< 50/min,~* Taking amiodarone~* Renal failure

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- sofosbuvir/daclatasvir (Type: EXPERIMENTAL): Once daily fixed-dose combination pill of sofosbuvir and daclatasvir for 12 weeks if the patient is non cirrhotic and for 24 weeks if cirrhotic

Based on this trial design, predict the completion outcome and termination type (if applicable).